公开(公告)号：US12053500B2

公开(公告)日：2024-08-06

申请号：US17644990

申请日：2021-12-17

Applicant: Sami-Sabinsa Group Limited

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Lakshmi Mundkur ,  A. Muhamad Ibrahim

IPC: A61K36/9066 ,  A23L33/105 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/12 ,  A61K31/19 ,  A61K31/23 ,  A61K36/324 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42 ,  A61P3/06 ,  A61P19/02 ,  A61P39/06

CPC classification number: A61K36/9066 ,  A23L33/105 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4866 ,  A61K31/12 ,  A61K31/19 ,  A61K31/23 ,  A61K36/324 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42 ,  A61P3/06 ,  A61P19/02 ,  A61P39/06

Abstract: A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises a Nigella sativa extract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.